益气活血解毒方外泌体样纳米囊泡的分离及其抗卵巢癌活性
本研究从益气活血解毒汤(YQHXJDD)中分离外泌体样纳米囊泡(ELNVs),筛选最佳煎煮方案并表征其成分,并在ID8-Luc腹膜荷瘤小鼠模型中验证抗卵巢癌活性。结果显示该ELNVs可抑制肿瘤生长与转移,并调节外周血TNF-α及网膜组织M1/M2巨噬细胞和CD4+/CD8+ T细胞比例。
要点
- 最佳煎煮方案为武火40分钟后再文火30分钟,可最大化YQHXJDD ELNVs产量。
- YQHXJDD ELNVs平均zeta电位为-35.52 mV,胶体稳定性良好。
- YQHXJDD ELNVs可抑制卵巢癌生长转移并正向调节局部免疫细胞比例。
核心结论
- 从YQHXJDD中分离的煎煮ELNVs可抑制卵巢癌的生长和播散。
- ELNVs包裹的miRNAs和脂质成分可能是其抗卵巢癌作用的关键介质。
研究设计与样本
- 研究采用不同煎煮方案提取YQHXJDD,通过梯度离心和超速离心富集ELNVs。
- 用透射电镜和纳米颗粒追踪分析表征ELNVs的粒径和浓度,计算每剂YQHXJDD富集的ELNVs数量以筛选煎煮方法。
- 建立ID8-Luc腹膜荷瘤小鼠模型,随机分为模型组、YQHXJDD组和YQHXJDD ELNVs组,连续灌胃3周。
- 采用小动物活体成像监测肿瘤负荷,免疫荧光定量网膜肿瘤中CD86、CD206、CD4和CD8荧光。
- 用Luminex xMAP®多重检测血清36种细胞因子/趋化因子,流式细胞术分析脾免疫细胞比例和活性。
主要发现
- 最佳煎煮方案为武火40分钟后再文火30分钟,ELNVs形成效率最高。
- 该方案制备的YQHXJDD ELNVs平均zeta电位为-35.52 mV,胶体稳定性良好。
- 非靶向代谢组学显示脂质和脂类样分子为最丰富代谢物超类(占总代谢物34.98%),羧酸及其衍生物为主要亚类(11.66%)。
- YQHXJDD ELNVs中富集的小RNA为典型功能性小RNA,miR8783等miRNA表达显著高且保守丰度高。
- 与模型组相比,YQHXJDD ELNVs显著抑制卵巢癌生长和转移,升高外周血TNF-α水平,正向调节网膜组织M1/M2巨噬细胞比例和CD4+/CD8+ T细胞比例(均P < 0.05)。
临床怎么用
- YQHXJDD ELNVs在动物模型中显示抗卵巢癌活性,提示其作为中药来源纳米治疗策略的潜在价值。
- 最佳煎煮方案(武火40分钟+文火30分钟)可为后续ELNVs制备提供参考。
- ELNVs中的miR8783等miRNA和脂质成分可能作为质量标志物或机制研究靶点。
- 脾免疫细胞比例未显著改变,提示ELNVs免疫调节作用可能具有局部组织倾向性。
局限性
- 研究仅在小鼠模型中进行,尚未在人体中验证疗效和安全性。
- ELNVs中miRNAs和脂质成分的抗癌机制仅为推测,未进行直接功能验证。
- 未报告ELNVs的剂量-效应关系及长期毒性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ovarian cancer, the deadliest gynecologic malignancy, is marked by high recurrence and poor prognosis. Exosome-like nanovesicles (ELNVs) derived from decocted traditional Chinese medicine (TCM) formulas encapsulate key bioactive components, and show promising therapeutic efficacy with good biocompatibility and targeting ability. However, research on ELNV extraction methodologies remains limited. Yiqi Huoxue Jiedu Decoction (YQHXJDD), an empirically validated TCM formula for ovarian cancer, lacks systematic investigation into its ELNV isolation protocols and therapeutic mechanisms. This study took YQHXJDD as the research subject, with a focus on extracting ELNVs from this TCM formula and validating their anti-ovarian cancer activity. METHODS: YQHXJDD was extracted using varied decoction protocols. ELNVs were enriched by gradient and ultracentrifugation, resuspended in phosphate-buffered saline, and were characterized by size and concentration using transmission electron microscopy (TEM) and nanoparticle tracking analysis (NTA). The number of ELNVs enriched per dose of YQHXJDD was calculated to screen the decoction method that maximized ELNV yield and aligned with clinical medication practices. The colloidal stability of YQHXJDD ELNVs was evaluated via zeta potential measurement, and the bioactive components of YQHXJDD ELNVs were identified using untargeted metabolomics and RNA sequencing. An ID8-Luc peritoneal tumor-bearing mouse model was established and randomized into three groups: model, YQHXJDD, and YQHXJDD ELNVs. Mice received oral gavage for 3 consecutive weeks. Tumor burden was monitored via in vivo small animal imaging. Immunofluorescence was used to quantify CD86, CD206, CD4, and CD8 fluorescence in omental tumors. Luminex xMAP® Multiplex Assay was used to detect 36 cytokines/chemokines in serum, and flow cytometry was used to analyze splenic immune cell proportions and activity. RESULTS: The creation efficiency of ELNVs formed during decoction is the highest with the optimal protocol, which is identified for maximizing YQHXJDD ELNV yield and involves 40 min of high-heat treatment followed by an additional 30 min of low-heat treatment. Zetaview-based zeta potential analysis demonstrated that YQHXJDD ELNVs by this protocol had an average zeta potential of -35.52 mV, indicating favorable colloidal stability. Untargeted metabolomics analysis revealed "Lipids and lipid-like molecules" as the most abundant metabolite superclass (34.98% of total metabolites), while "Carboxylic acids and derivatives" represented the dominant subclass (11.66%). Regarding small RNAs, those enriched in YQHXJDD ELNVs were confirmed to be typical, functionally active small RNAs. Notably, miR8783 and other miRNAs exhibited significantly high expression, along with high conservation and abundance across samples, suggesting they might act as core regulators of YQHXJDD ELNV biological functions. In in vivo assessments, compared with the model group, YQHXJDD ELNVs significantly inhibited ovarian cancer growth and metastasis, increased tumor necrosis factor-α (TNF-α) levels in mouse peripheral blood, and positively regulated the M1/M2 macrophage ratio and CD4+/CD8+ T cell ratio in omental tissues (all P < 0.05). However, YQHXJDD ELNVs had no significant effect on the proportions of splenic effector T cells, natural killer (NK) cells, activated CD8+ T cells, and activated NK cells (all P ≥ 0.05). CONCLUSION: The decoction ELNVs isolated from YQHXJDD can inhibit the growth and dissemination of ovarian cancer. The miRNAs and lipid components encapsulated in these ELNVs are presumed to be the critical mediators of these anti-ovarian cancer effects.
引用
- Song QY, Cui YJ, Lu WP, et al. Isolation of exosome-like nanovesicles from Yiqi Huoxue Jiedu decoction and their anti-ovarian cancer activity. Front Pharmacol. 2025. PMID: 41170390. doi:10.3389/fphar.2025.1680551
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。